PDS Biotechnology Q2 2022 Earnings Report
Key Takeaways
PDS Biotechnology reported a net loss of $5.8 million for the second quarter of 2022, compared to a net loss of $0.6 million for the same period in 2021. The increased loss was primarily due to higher research and development expenses and general and administrative costs. The company's cash balance as of June 30, 2022, was $53.0 million.
Granted Fast Track Designation by FDA for PDS0101 in combination with KEYTRUDA® for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.
Presented clinical efficacy data from the VERSATILE-002 Phase 2 clinical trial at ASCO 2022, with 76.5% of patients demonstrating clinical efficacy.
Announced acceptance of clinical trial application to expand VERSATILE-002 Phase 2 trial into the United Kingdom.
Presented pre-clinical data on universal flu vaccine program at the American Society of Virology meeting.